Page 148 - Binder2

• Proteins are manufactured with cleaner expression
systems that reduce ADA risk
• Delivery platforms are built to mimic natural
immune exposures—oral, mucosal, micro-dosed
• Tolerogenic adjuvants teach the immune system to
see the therapy not as a threat, but as something to
live with

We stop treating the immune system like a problem to
manage, and start treating it like a partner to instruct.

Durability becomes part of the molecule, not just part of
the marketing.
Immunogenicity is not a side metric—it’s a core
performance indicator.
Drug survival becomes a feature, not a fluke.

This isn’t just good medicine.
It’s good economics.

Because when a biologic lasts—when it continues to work
without provoking immune rejection—it doesn’t just
improve outcomes. It reduces waste across the entire
healthcare ecosystem.

Benefit of
Durable Explanation
Biologics
Durable biologics reduce the need to
change therapies. Each switch involves
diagnostics, authorizations, pharmacy
Fewer switches
approvals, onboarding, and education—
incurring time, cost, and effort not
captured on balance sheets.

146